Pathogenesis and management of pruritus in PBC and PSC

Digestive Diseases

Volumn 33, Issue , 2015, Pages 164-175

  Kremer, Andreas E ^a   Namer, Barbara ^b   Bolier, Ruth ^c   Fischer, Michael J ^b   Oude Elferink, Ronald P ^c   Beuers, Ulrich ^c  

^a Department of Medicine ^*

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Autotaxin; Bile salt; Cholestasis; Liver; Lysophosphatidic acid; Pruritus

Indexed keywords

ANION EXCHANGE RESIN; ANTIPRURITIC AGENT; BILIRUBIN; CALCITONIN GENE RELATED PEPTIDE; COLESTYRAMINE; CORTICOSTEROID; ENDOTHELIN 1; ESTROGEN; G PROTEIN COUPLED RECEPTOR; GASTRIN; HISTAMINE; INTERLEUKIN 13; NALTREXONE; OPIATE; PROGESTERONE; RIFAMPICIN; SERTRALINE; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; VESICULAR GLUTAMATE TRANSPORTER 2;

ARTICLE; BILE DUCT INJURY; CHOLESTASIS; ENZYME ACTIVITY; FATIGUE; HEPATIC STELLATE CELL; HORMONE SUBSTITUTION; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER TRANSPLANTATION; MALARIA; MENSTRUAL CYCLE; NONALCOHOLIC FATTY LIVER; OVERALL SURVIVAL; PLASMAPHERESIS; PREVALENCE; PROTHROMBIN TIME; PRURITUS; SENSORY NERVE CELL; SIGNAL TRANSDUCTION; UPREGULATION; BILIARY CIRRHOSIS; COMPLICATION; PATHOPHYSIOLOGY; SCLEROSING CHOLANGITIS;

CHOLANGITIS, SCLEROSING; CHOLESTASIS; HUMANS; LIVER CIRRHOSIS, BILIARY; PRURITUS; SIGNAL TRANSDUCTION;

EID: 84977466653     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000440829     Document Type: Article

References (138)

1. Schmelz M, Schmidt R, Bickel A, Handwerker HO, Torebjörk HE: Specific C-receptors for itch in human skin. J Neurosci 1997;17:8003-8008.
2. Yosipovitch G, Bernhard JD: Clinical practice. Chronic pruritus. N Engl J Med 2013; 368:1625-1634.
3. Paus R, Schmelz M, Bíró T, Steinhoff M: Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest 2006;116:1174-1186.
4. Kremer AE, Feramisco J, Reeh PW, Beuers U, Oude Elferink RP: Receptors, cells and circuits involved in pruritus of systemic disorders. Biochim Biophys Acta 2014;1842:869-892.
5. Reich A, Ständer S, Szepietowski JC: Drug-induced pruritus: a review. Acta Derm Venereol 2009;89:236-244.
6. Liu Q, Tang Z, Surdenikova L, Kim S, Patel KN, Kim A, Ru F, Guan Y, Weng HJ, Geng Y, Undem BJ, Kollarik M, Chen ZF, Anderson DJ, Dong X: Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus. Cell 2009;139:1353-1365.
7. Liu Q, Sikand P, Ma C, Tang Z, Han L, Li Z, Sun S, LaMotte RH, Dong X: Mechanisms of itch evoked by β-alanine. J Neurosci 2012;32: 14532-14537.
8. Liu XY, Liu ZC, Sun YG, Ross M, Kim S, Tsai FF, Li QF, Jeffry J, Kim JY, Loh HH, Chen ZF: Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids. Cell 2011;147:447-458.
9. McQueen DS, Noble MA, Bond SM: Endothelin-1 activates ETA receptors to cause reflex scratching in BALB/c mice. Br J Pharmacol 2007;151:278-284.
10. Liu T, Berta T, Xu ZZ, Park CK, Zhang L, Lü N, Liu Q, Liu Y, Gao YJ, Liu YC, Ma Q, Dong X, Ji RR: TLR3 deficiency impairs spinal cord synaptic transmission, central sensitization, and pruritus in mice. J Clin Invest 2012;122: 2195-2207.
11. Liu T, Xu ZZ, Park CK, Berta T, Ji RR: Toll-like receptor 7 mediates pruritus. Nat Neurosci 2010;13:1460-1462.
12. Kim SJ, Park GH, Kim D, Lee J, Min H, Wall E, Lee CJ, Simon MI, Lee SJ, Han SK: Analysis of cellular and behavioral responses to imiquimod reveals a unique itch pathway in transient receptor potential vanilloid 1 (TRPV1)-expressing neurons. Proc Natl Acad Sci U S A 2011;108:3371-3376.
13. Zheng T, Oh MH, Oh SY, Schroeder JT, Glick AB, Zhu Z: Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol 2009;129:742-751.
14. Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, Haugen HS, Maurer M, Harder B, Johnston J, Bort S, Mudri S, Kuijper JL, Bukowski T, Shea P, Dong DL, Dasovich M, Grant FJ, Lockwood L, Levin SD, LeCiel C, Waggie K, Day H, Topouzis S, Kramer J, Kuestner R, Chen Z, Foster D, Parrish-Novak J, Gross JA: Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004;5:752-760.
15. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009;51:237-267.
16. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases: Primary biliary cirrhosis. Hepatology 2009;50:291-308.
17. Kremer AE, Oude Elferink RP, Beuers U: Pathophysiology and current management of pruritus in liver disease. Clin Res Hepatol Gastroenterol 2011;35:89-97.
18. Kremer AE, Beuers U, Oude-Elferink RP, Pusl T: Pathogenesis and treatment of pruritus in cholestasis. Drugs 2008;68:2163-2182.
19. Geenes V, Williamson C: Intrahepatic cholestasis of pregnancy. World J Gastroenterol 2009;15:2049-2066.
20. Sherlock S, Scheuer PJ: The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med 1973;289:674-678.
21. James O, Macklon AF, Watson AJ: Primary biliary cirrhosis - a revised clinical spectrum. Lancet 1981;1:1278-1281.
22. Bergasa NV, Mehlman JK, Jones EA: Pruritus and fatigue in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 2000; 14:643-655.
23. Koulentaki M, Ioannidou D, Stefanidou M, Maraki S, Drigiannakis I, Dimoulios P, Melono JM, Tosca A, Kouroumalis EA: Dermatological manifestations in primary biliary cirrhosis patients: a case control study. Am J Gastroenterol 2006;101:541-546.
24. McPhedran NT, Henderson RD: Pruritus and jaundice. Can Med Assoc J 1965;92:1258-1260.
25. Cribier B, Samain F, Vetter D, Heid E, Grosshans E: Systematic cutaneous examination in hepatitis C virus infected patients. Acta Derm Venereol 1998;78:355-357.
26. Chia SC, Bergasa NV, Kleiner DE, Goodman Z, Hoofnagle JH, Di Bisceglie AM: Pruritus as a presenting symptom of chronic hepatitis C. Dig Dis Sci 1998;43:2177-2183.
27. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, Opolon P: Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC group. Multidepartment virus C. Arthritis Rheum 1999;42:2204-2212.
28. Ghent CN, Bloomer JR: Itch in liver disease: facts and speculations. Yale J Biol Med 1979; 52:77-82.
29. Mells GF, Pells G, Newton JL, Bathgate AJ, Burroughs AK, Heneghan MA, Neuberger JM, Day DB, Ducker SJ, Sandford RN, Alexander GJ, Jones DE; UK-PBC Consortium: Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology 2013;58:273-283.
30. Elias E, Burra P: Primary biliary cirrhosis: symptomatic treatment. J Gastroenterol Hepatol 1991;6:570-573.
31. Elias E: Liver transplantation. J R Coll Physicians Lond 1993;27:224-232.
32. Heathcote EJ: Management of primary biliary cirrhosis. The American association for the study of liver diseases practice guidelines. Hepatology 2000;31:1005-1013.
33. Neuberger J, Jones EA: Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy. Eur J Gastroenterol Hepatol 2001;13: 1393-1394.
34. Pusl T, Beuers U: Ursodeoxycholic acid treatment of vanishing bile duct syndromes. World J Gastroenterol 2006;12:3487-3495.
35. Bergasa NV: The pruritus of cholestasis. J Hepatol 2005;43:1078-1088.
36. Talwalkar JA, Souto E, Jorgensen RA, Lindor KD: Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2003;1:297-302.
37. Swain MG: Pruritus and lethargy in the primary billary cirrhosis patient; in Neuberger J (eds): Primary Biliary Cirrhosis. Eastbourne, West End Studios, 1999, pp 75-81.
38. McNeil B, Dong X: Peripheral mechanisms of itch. Neurosci Bull 2012;28:100-110.
39. Cevikbas F, Steinhoff M, Ikoma A: Role of spinal neurotransmitter receptors in itch: new insights into therapies and drug development. CNS Neurosci Ther 2011;17:742-749.
40. LaMotte RH, Shimada SG, Sikand P: Mouse models of acute, chemical itch and pain in humans. Exp Dermatol 2011;20:778-782.
41. LaMotte RH, Dong X, Ringkamp M: Sensory neurons and circuits mediating itch. Nat Rev Neurosci 2014;15:19-31.
42. Yosipovitch G, Greaves MW, Schmelz M: Itch. Lancet 2003;361:690-694.
43. Bergasa NV: The itch of liver disease. Semin Cutan Med Surg 2011;30:93-98.
44. Kremer AE, Martens JJ, Kulik W, Ruëff F, Kuiper EM, van Buuren HR, van Erpecum KJ, Kondrackiene J, Prieto J, Rust C, Geenes VL, Williamson C, Moolenaar WH, Beuers U, Oude Elferink RP: Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 2010;139:1008-1018.
45. von Frey M: Zur Physiologie des Juckreizes. Arch Neerl Physiol 1922;7:142-145.
46. Shelley WB, Arthur RP: The neurohistology and neurophysiology of the itch sensation in man. AMA Arch Derm 1957;76:296-323.
47. McMahon SB, Koltzenburg M: Itching for an explanation. Trends Neurosci 1992;15:497-501.
48. Green BG, Shaffer GS: The sensory response to capsaicin during repeated topical exposures: differential effects on sensations of itching and pungency. Pain 1993;53:323-334.
49. Ikoma A, Steinhoff M, Ständer S, Yosipovitch G, Schmelz M: The neurobiology of itch. Nat Rev Neurosci 2006;7:535-547.
50. Davidson S, Zhang X, Yoon CH, Khasabov SG, Simone DA, Giesler GJ Jr: The itch-producing agents histamine and cowhage activate separate populations of primate spinothalamic tract neurons. J Neurosci 2007;27: 10007-10014.
51. Sun YG, Zhao ZQ, Meng XL, Yin J, Liu XY, Chen ZF: Cellular basis of itch sensation. Science 2009;325:1531-1534.
52. Sikand P, Shimada SG, Green BG, LaMotte RH: Sensory responses to injection and punctate application of capsaicin and histamine to the skin. Pain 2011;152:2485-2494.
53. Han L, Ma C, Liu Q, Weng HJ, Cui Y, Tang Z, Kim Y, Nie H, Qu L, Patel KN, Li Z, McNeil B, He S, Guan Y, Xiao B, Lamotte RH, Dong X: A subpopulation of nociceptors specifically linked to itch. Nat Neurosci 2013;16:174-182.
54. Namer B, Carr R, Johanek LM, Schmelz M, Handwerker HO, Ringkamp M: Separate peripheral pathways for pruritus in man. J Neurophysiol 2008;100:2062-2069.
55. Namer B, Reeh P: Scratching an itch. Nat Neurosci 2013;16:117-118.
56. Weisshaar E, Szepietowski JC, Darsow U, Misery L, Wallengren J, Mettang T, Gieler U, Lotti T, Lambert J, Maisel P, Streit M, Greaves MW, Carmichael AJ, Tschachler E, Ring J, Ständer S: European guideline on chronic pruritus. Acta Derm Venereol 2012;92:563-581.
57. Ballantyne JC, Loach AB, Carr DB: Itching after epidural and spinal opiates. Pain 1988;33: 149-160.
58. Ballantyne JC, Loach AB, Carr DB: The incidence of pruritus after epidural morphine. Anaesthesia 1989;44:863.
59. Atanassoff PG, Brull SJ, Zhang J, Greenquist K, Silverman DG, Lamotte RH: Enhancement of experimental pruritus and mechanically evoked dysesthesiae with local anesthesia. Somatosens Mot Res 1999;16:291-298.
60. Ross SE, Mardinly AR, McCord AE, Zurawski J, Cohen S, Jung C, Hu L, Mok SI, Shah A, Savner EM, Tolias C, Corfas R, Chen S, Inquimbert P, Xu Y, McInnes RR, Rice FL, Corfas G, Ma Q, Woolf CJ, Greenberg ME: Loss of inhibitory interneurons in the dorsal spinal cord and elevated itch in Bhlhb5 mutant mice. Neuron 2010;65:886-898.
61. Ross SE, McCord AE, Jung C, Atan D, Mok SI, Hemberg M, Kim TK, Salogiannis J, Hu L, Cohen S, Lin Y, Harrar D, McInnes RR, Greenberg ME: Bhlhb5 and Prdm8 form a repressor complex involved in neuronal circuit assembly. Neuron 2012;73:292-303.
62. Liu Y, Abdel Samad O, Zhang L, Duan B, Tong Q, Lopes C, Ji RR, Lowell BB, Ma Q: VGLUT2-dependent glutamate release from nociceptors is required to sense pain and suppress itch. Neuron 2010;68:543-556.
63. Lagerström MC, Rogoz K, Abrahamsen B, Persson E, Reinius B, Nordenankar K, Olund C, Smith C, Mendez JA, Chen ZF, Wood JN, Wallén-Mackenzie A, Kullander K: VGLUT2-dependent sensory neurons in the TRPV1 population regulate pain and itch. Neuron 2010;68:529-542.
64. Han L, Dong X: Itch mechanisms and circuits. Annu Rev Biophys 2014;43:331-355.
65. Dong X, Han S, Zylka MJ, Simon MI, Anderson DJ: A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons. Cell 2001;106:619-632.
66. Reddy VB, Iuga AO, Shimada SG, LaMotte RH, Lerner EA: Cowhage-evoked itch is mediated by a novel cysteine protease: a ligand of protease-activated receptors. J Neurosci 2008; 28:4331-4335.
67. Reddy VB, Shimada SG, Sikand P, Lamotte RH, Lerner EA: Cathepsin S elicits itch and signals via protease-activated receptors. J Invest Dermatol 2010;130:1468-1470.
68. Liu Q, Weng HJ, Patel KN, Tang Z, Bai H, Steinhoff M, Dong X: The distinct roles of two GPCRs, MrgprC11 and PAR2, in itch and hyperalgesia. Sci Signal 2011;4:ra45.
69. Wilson SR, Gerhold KA, Bifolck-Fisher A, Liu Q, Patel KN, Dong X, Bautista DM: TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch. Nat Neurosci 2011;14:595-602.
70. Mishra SK, Hoon MA: The cells and circuitry for itch responses in mice. Science 2013;340: 968-971.
71. Sun YG, Chen ZF: A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 2007;448:700-703.
72. Beuers U, Kremer AE, Bolier R, Elferink RP: Pruritus in cholestasis: facts and fiction. Hepatology 2014;60:399-407.
73. Bolier R, Oude Elferink RP, Beuers U: Advances in pathogenesis and treatment of pruritus. Clin Liver Dis 2013;17:319-329.
74. Stapelbroek JM, van Erpecum KJ, Klomp LW, Venneman NG, Schwartz TP, van Berge Henegouwen GP, Devlin J, van Nieuwkerk CM, Knisely AS, Houwen RH: Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis. Hepatology 2006;43:51-53.
75. Beuers U, Gerken G, Pusl T: Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis. Hepatology 2006;44: 280-281.
76. Hashimoto T, Ohata H, Momose K: Itch-scratch responses induced by lysophosphatidic acid in mice. Pharmacology 2004;72:51-56.
77. van Meeteren LA, Moolenaar WH: Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res 2007;46:145-160.
78. Houben AJ, Moolenaar WH: Autotaxin and LPA receptor signaling in cancer. Cancer Metastasis Rev 2011;30:557-565.
79. Choi JW, Chun J: Lysophospholipids and their receptors in the central nervous system. Biochim Biophys Acta 2013;1831:20-32.
80. Nieto-Posadas A, Picazo-Juárez G, Llorente I, Jara-Oseguera A, Morales-Lázaro S, Escalante-Alcalde D, Islas LD, Rosenbaum T: Lysophosphatidic acid directly activates TRPV1 through a C-terminal binding site. Nat Chem Biol 2011;8:78-85.
81. Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, Yasuda K, Fukuzawa K: Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 2002;277:39436-39442.
82. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, Arai H: Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002;158:227-233.
83. Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, Noji S, Yatomi Y, Aoki J, Arai H: Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem 2006; 281:25822-25830.
84. Moolenaar WH, Perrakis A: Insights into autotaxin: how to produce and present a lipid mediator. Nat Rev Mol Cell Biol 2011;12:674-679.
85. Kremer AE, Martens JJ, Kulik W, Williamson C, Moolenaar WH, Kondrackiene J, Beuers U, Oude Elferink RP: Autotaxin but not bile salts correlate with itch intensity in cholestasis. J Hepatol 2010;52:S1.
86. Kremer AE, van Dijk R, Leckie P, Schaap FG, Kuiper EM, Mettang T, Reiners KS, Raap U, van Buuren HR, van Erpecum KJ, Davies NA, Rust C, Engert A, Jalan R, Oude Elferink RP, Beuers U: Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology 2012;56:1391-1400.
87. Kremer AE, Bolier R, Dixon PH, Geenes V, Chambers J, Tolenaars D, Ris-Stalpers C, Kaess BM, Rust C, van der Post JA, Williamson C, Beuers U, Oude Elferink RP: Autotaxin activity has a high accuracy to diagnose intrahepatic cholestasis of pregnancy. J Hepatol 2015;62:897-904.
88. Shimizu Y, Murao K, Tanaka T, Kubo Y, Tokumura A: Increased lysophospholipase D activity of autotaxin in sera of patients with atopic dermatitis. J Dermatol Sci 2014;74: 162-165.
89. Nakao M, Sugaya M, Suga H, Kawaguchi M, Morimura S, Kai H, Ohmatsu H, Fujita H, Asano Y, Tada Y, Kadono T, Sato S: Serum autotaxin levels correlate with pruritus in patients with atopic dermatitis. J Invest Dermatol 2014;134:1745-1747.
90. Shimizu Y, Morikawa Y, Okudaira S, Kimoto S, Tanaka T, Aoki J, Tokumura A: Potentials of the circulating pruritogenic mediator lysophosphatidic acid in development of allergic skin inflammation in mice: role of blood cell-associated lysophospholipase D activity of autotaxin. Am J Pathol 2014;184:1593-1603.
91. Jones EA, Bergasa NV: The pruritus of cholestasis: from bile acids to opiate agonists. Hepatology 1990;11:884-887.
92. Schaap FG, Trauner M, Jansen PL: Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol 2014;11:55-67.
93. Trauner M, Baghdasaryan A, Claudel T, Fickert P, Halilbasic E, Moustafa T, Zollner G: Targeting nuclear bile acid receptors for liver disease. Dig Dis 2011;29:98-102.
94. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D: Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013;145:574-582.e1.
95. Fiorucci S, Cipriani S, Mencarelli A, Baldelli F, Bifulco G, Zampella A: Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA. Mini Rev Med Chem 2011;11:753-762.
96. Alemi F, Kwon E, Poole DP, Lieu T, Lyo V, Cattaruzza F, Cevikbas F, Steinhoff M, Nassini R, Materazzi S, Guerrero-Alba R, Valdez-Morales E, Cottrell GS, Schoonjans K, Geppetti P, Vanner SJ, Bunnett NW, Corvera CU: The TGR5 receptor mediates bile acid-induced itch and analgesia. J Clin Invest 2013; 123:1513-1530.
97. Lieu T, Jayaweera G, Zhao P, Poole DP, Jensen D, Grace M, McIntyre P, Bron R, Wilson YM, Krappitz M, Haerteis S, Korbmacher C, Steinhoff MS, Nassini R, Materazzi S, Geppetti P, Corvera CU, Bunnett NW: The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice. Gastroenterology 2014;147:1417-1428.
98. Beuers U, Spengler U, Zwiebel FM, Pauletzki J, Fischer S, Paumgartner G: Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease. Hepatology 1992;15:603-608.
99. Keitel V, Spomer L, Marin JJ, Williamson C, Geenes V, Kubitz R, Häussinger D, Macias RI: Effect of maternal cholestasis on TGR5 expression in human and rat placenta at term. Placenta 2013;34:810-816.
100. Greaves MW: Antihistamines in dermatology. Skin Pharmacol Physiol 2005;18:220-229.
101. Beuers U: Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006;3:318-328.
102. Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, Ponsioen CY, Floreani A, Corpechot C, Mayo MJ, Battezzati PM, Pares A, Nevens F, Burroughs AK, Kowdley KV, Trivedi PJ, Kumagi T, Cheung A, Lleo A, Imam MH, Boonstra K, Cazzagon N, Franceschet I, Poupon R, Caballeria L, Pieri G, Kanwar PS, Lindor KD, Hansen BE: Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014; 147: 1338-1349.e5; quiz e15.
103. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ: Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113: 884-890.
104. Parés A, Caballeria L, Rodés J: Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006;130:715-720.
105. Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, Houben MH, Witteman BJ, van Erpecum KJ, van Buuren HR; Dutch PBC Study Group: Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009;136: 1281-1287.
106. Chappell LC, Gurung V, Seed PT, Chambers J, Williamson C, Thornton JG; PITCH Study Consortium: Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ 2012; 344:e3799.
107. Lindor KD: Ursodiol for primary sclerosing cholangitis. Mayo primary sclerosing cholangitis-ursodeoxycholic acid study group. N Engl J Med 1997;336:691-695.
108. Van Itallie TB, Hashim SA, Crampton RS, Tennent DM: The treatment of pruritus and hypercholesteremia of primary biliary cirrhosis with cholestyramine. N Engl J Med 1961;265:469-474.
109. Carey JB Jr, Williams G: Relief of the pruritus of jaundice with a bile-acid sequestering resin. JAMA 1961;176:432-435.
110. Oster ZH, Rachmilewitz EA, Moran E, Stein Y: Relief of pruritus by cholestyramine in chronic liver disease. Isr J Med Sci 1965;1: 599-606.
111. Datta DV, Sherlock S: Treatment of pruritus of obstructive jaundice with cholestyramine. Br Med J 1963;1:216-219.
112. Datta DV, Sherlock S: Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology 1966;50:323-332.
113. Di Padova C, Tritapepe R, Rovagnati P, Rossetti S: Double-blind placebo-controlled clinical trial of microporous cholestyramine in the treatment of intra- and extra-hepatic cholestasis: relationship between itching and serum bile acids. Methods Find Exp Clin Pharmacol 1984;6:773-776.
114. Duncan JS, Kennedy HJ, Triger DR: Treatment of pruritus due to chronic obstructive liver disease. Br Med J (Clin Res Ed) 1984; 289:22.
115. Pusl T, Beuers U: Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol 2005;28:147-157.
116. Kuiper EM, van Erpecum KJ, Beuers U, Hansen BE, Thio HB, de Man RA, Janssen HL, van Buuren HR: The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology 2010;52:1334-1340.
117. Ghent CN, Carruthers SG: Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988;94: 488-493.
118. Podesta A, Lopez P, Terg R, Villamil F, Flores D, Mastai R, Udaondo CB, Companc JP: Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci 1991;36:216-220.
119. Bachs L, Parés A, Elena M, Piera C, Rodés J: Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989;1:574-576.
120. Bachs L, Parés A, Elena M, Piera C, Rodés J: Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992;102:2077-2080.
121. Carson KL, Tran TT, Cotton P, Sharara AI, Hunt CM: Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Am J Gastroenterol 1996;91: 1022-1023.
122. Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR: Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997;113:1264-1269.
123. Terg R, Coronel E, Sordá J, Muñoz AE, Findor J: Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002;37:717-722.
124. Mansour-Ghanaei F, Taheri A, Froutan H, Ghofrani H, Nasiri-Toosi M, Bagherzadeh AH, Farahvash MJ, Mirmomen S, Ebrahimi-Dariani N, Farhangi E, Pourrasouli Z: Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 2006;12: 1125-1128.
125. Jones EA, Neuberger J, Bergasa NV: Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. QJM 2002;95:547-552.
126. McRae CA, Prince MI, Hudson M, Day CP, James OF, Jones DE: Pain as a complication of use of opiate antagonists for symptom control in cholestasis. Gastroenterology 2003;125:591-596.
127. Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ: Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007;45:666-674.
128. Browning J, Combes B, Mayo MJ: Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2003; 98:2736-2741.
129. Huesmann M, Huesmann T, Osada N, Phan NQ, Kremer AE, Ständer S: Cholestatic pruritus: a retrospective analysis on clinical characteristics and treatment response. J Dtsch Dermatol Ges 2013;11:158-168.
130. Lens S, Leoz M, Nazal L, Bruguera M, Parés A: Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int 2014;34:197-203.
131. Decock S, Roelandts R, Steenbergen WV, Laleman W, Cassiman D, Verslype C, Fevery J, Pelt JV, Nevens F: Cholestasis-induced pruritus treated with ultraviolet B phototherapy: an observational case series study. J Hepatol 2012;57:637-641.
132. Cohen LB, Ambinder EP, Wolke AM, Field SP, Schaffner F: Role of plasmapheresis in primary biliary cirrhosis. Gut 1985;26:291-294.
133. Fuhrmann V, Drolz A, Trauner M: Extra-corporeal artificial liver support systems in the management of intractable cholestatic pruritus. Liver Int 2011;31(suppl 3):31-33.
134. Macia M, Avilés J, Navarro J, Morales S, García J: Efficacy of molecular adsorbent recirculating system for the treatment of intractable pruritus in cholestasis. Am J Med 2003; 114:62-64.
135. Parés A, Cisneros L, Salmerón JM, Caballería L, Mas A, Torras A, Rodés J: Extra-corporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2004;99:1105-1110.
136. Leckie P, Tritto G, Mookerjee R, Davies N, Jones D, Jalan R: 'Out-patient' albumin dialysis for cholestatic patients with intractable pruritus. Aliment Pharmacol Ther 2012; 35:696-704.
137. Parés A, Herrera M, Avilés J, Sanz M, Mas A: Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol 2010;53:307-312.
138. Pusl T, Denk GU, Parhofer KG, Beuers U: Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis. J Hepatol 2006;45: 887-891.